EA202191325A1 - ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17a-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ - Google Patents
ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17a-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫInfo
- Publication number
- EA202191325A1 EA202191325A1 EA202191325A EA202191325A EA202191325A1 EA 202191325 A1 EA202191325 A1 EA 202191325A1 EA 202191325 A EA202191325 A EA 202191325A EA 202191325 A EA202191325 A EA 202191325A EA 202191325 A1 EA202191325 A1 EA 202191325A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- oxaestra
- homo
- methyl
- breast cancer
- sulfamoyloxi
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000005075 mammary gland Anatomy 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к области медицины и химико-фармацевтической промышленности и касается средств для лечения рака молочной железы. Описано применение 3-O-сульфамоилокси-7-метил-D-гомо-6-оксаэстра-1,3,5(10),8(9)-тетраен-17а-она в качестве противоонкологического агента при моно- и адъювантной терапии рака молочной железы, включая трижды негативную форму.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2018139337A RU2678845C1 (ru) | 2018-11-08 | 2018-11-08 | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7β-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ НЕГАТИВНУЮ ФОРМУ |
PCT/RU2019/000651 WO2020096487A1 (ru) | 2018-11-08 | 2019-09-19 | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7β-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191325A1 true EA202191325A1 (ru) | 2021-08-06 |
Family
ID=65273827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191325A EA202191325A1 (ru) | 2018-11-08 | 2019-09-19 | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17a-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220160676A1 (ru) |
EP (1) | EP3878455A4 (ru) |
CN (1) | CN114007624A (ru) |
EA (1) | EA202191325A1 (ru) |
RU (1) | RU2678845C1 (ru) |
WO (1) | WO2020096487A1 (ru) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19712488A1 (de) * | 1997-03-25 | 1998-10-01 | Knoell Hans Forschung Ev | Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben |
US6046186A (en) | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
RU2620084C1 (ru) * | 2016-02-29 | 2017-05-23 | Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) | Сульфаматы 2-этил-6-оксаэстра-1,3,5(10),8,14-пентаенов в качестве ингибиторов пролиферации опухолевых клеток MCF-7 |
RU2619457C1 (ru) * | 2016-04-29 | 2017-05-16 | Федеральное государственное автономное образовательное учреждение высшего образования "Дальневосточный федеральный университет" (ДВФУ) | 7β-Метил-3,17αβ-дисульфамоилокси-D-гомо-6-окса-эстра-1,3,5(10),8,14-пентаен в качестве ингибитора роста клеток рака молочной железы MCF-7 |
CN108721279B (zh) * | 2017-04-19 | 2021-06-29 | 安尼根有限公司 | 包含5′-羟基-5-硝基-靛玉红-3′-肟作为活性成分的乳腺癌治疗剂 |
-
2018
- 2018-11-08 RU RU2018139337A patent/RU2678845C1/ru active
-
2019
- 2019-09-19 WO PCT/RU2019/000651 patent/WO2020096487A1/ru active Application Filing
- 2019-09-19 US US17/292,690 patent/US20220160676A1/en active Pending
- 2019-09-19 EA EA202191325A patent/EA202191325A1/ru unknown
- 2019-09-19 EP EP19882498.9A patent/EP3878455A4/en active Pending
- 2019-09-19 CN CN201980088359.XA patent/CN114007624A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114007624A (zh) | 2022-02-01 |
EP3878455A4 (en) | 2022-12-07 |
RU2678845C1 (ru) | 2019-02-04 |
WO2020096487A1 (ru) | 2020-05-14 |
EP3878455A1 (en) | 2021-09-15 |
US20220160676A1 (en) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112015019064A8 (pt) | uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
MX2018012390A (es) | Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio. | |
MX2019015211A (es) | Compuestos para el tratamiento de tnbc. | |
AR112102A1 (es) | Tinostamustina para utilizar en el tratamiento de cáncer de ovario | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
MX2018016332A (es) | Quimioterapias de combinacion. | |
BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
BR112022008655A2 (pt) | Composições de copolímero em bloco responsivas ao ph, micelas, e métodos de uso | |
EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
EA202191323A1 (ru) | Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний | |
EA202092861A1 (ru) | Специфичные в отношении злокачественной опухоли t-клеточные рецепторы | |
CY1124183T1 (el) | Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης | |
EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
EA202191325A1 (ru) | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-7-МЕТИЛ-D-ГОМО-6-ОКСАЭСТРА-1,3,5(10),8(9)-ТЕТРАЕН-17a-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
EA201992852A1 (ru) | Схема дозирования тезетаксела и капецитабина |